Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04935359
Title Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | TUR | SWE | SVK | NOR | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUS

Facility Status City State Zip Country Details
Highlands Oncology Group Fayetteville Arkansas 72703 United States Details
University of California LA Los Angeles California 90095 United States Details
Advent Health Cancer Institute Orlando Florida 32804 United States Details
Fort Wayne Medical Oncology Hematology Inc Fort Wayne Indiana 46815 United States Details
NYU Clinical Cancer Center New York New York 10016 United States Details
US Oncology Research Dallas Dallas Texas 75204 United States Details
Houston Methodist Hospital Houston Texas 77030 United States Details
Huntsman Cancer Institute Salt Lake City Utah 84112 United States Details
Seattle Cancer Care Alliance Seattle Washington 98105 United States Details
Novartis Investigative Site Adelaide South Australia 5000 Australia Details
Novartis Investigative Site Perth Western Australia 6009 Australia Details
Novartis Investigative Site Bonheiden 2820 Belgium Details
Novartis Investigative Site Bruxelles 1200 Belgium Details
Novartis Investigative Site Edegem 2650 Belgium Details
Novartis Investigative Site Leuven 3000 Belgium Details
Novartis Investigative Site Brasilia Distrito Federal 70200-730 Brazil Details
Novartis Investigative Site Porto Alegre Rio Grande Do Sul 90035-001 Brazil Details
Novartis Investigative Site Ijui RS 98700-000 Brazil Details
Novartis Investigative Site Sao Paulo SP 04014-002 Brazil Details
Novartis Investigative Site Brampton Ontario L6R 3J7 Canada Details
Novartis Investigative Site Cambridge Ontario N1R 3G2 Canada Details
Novartis Investigative Site Toronto Ontario M4N 3M5 Canada Details
Novartis Investigative Site Guangzhou Guangdong 510000 China Details
Novartis Investigative Site Harbin Heilongjiang 150081 China Details
Novartis Investigative Site Nanjing Jiangsu 210029 China Details
Novartis Investigative Site Dalian Liaoning 116001 China Details
Novartis Investigative Site Jining Shandong 272000 China Details
Novartis Investigative Site Xian Shanxi 710061 China Details
Novartis Investigative Site Chengdu Sichuan 610041 China Details
Novartis Investigative Site Hangzhou Zhejiang 310022 China Details
Novartis Investigative Site Beijing 100021 China Details
Novartis Investigative Site Beijing 100036 China Details
Novartis Investigative Site Beijing 100730 China Details
Novartis Investigative Site Shanghai 200025 China Details
Novartis Investigative Site Shanghai 200032 China Details
Novartis Investigative Site Shanghai 200127 China Details
Novartis Investigative Site Shanghai 200433 China Details
Novartis Investigative Site Tianjin 300480 China Details
Novartis Investigative Site Brno Czech Republic 656 53 Czechia Details
Novartis Investigative Site Novy Jicin Czech Republic 74101 Czechia Details
Novartis Investigative Site Hradec Kralove CZE 500 05 Czechia Details
Novartis Investigative Site Praha 4 140 59 Czechia Details
Novartis Investigative Site Helsinki 00290 Finland Details
Novartis Investigative Site Tampere FIN-33521 Finland Details
Novartis Investigative Site Nice Alpes Maritimes 06189 France Details
Novartis Investigative Site Avignon 84082 France Details
Novartis Investigative Site Besancon Cedex 25030 France Details
Novartis Investigative Site Creteil 94010 France Details
Novartis Investigative Site Lyon 08 69373 France Details
Novartis Investigative Site Marseille 13273 France Details
Novartis Investigative Site Montpellier 34295 France Details
Novartis Investigative Site Nantes Cedex 1 44093 France Details
Novartis Investigative Site Paris 75015 France Details
Novartis Investigative Site Berlin 13353 Germany Details
Novartis Investigative Site Bochum 44791 Germany Details
Novartis Investigative Site Essen 45147 Germany Details
Novartis Investigative Site Frankfurt 60488 Germany Details
Novartis Investigative Site Halle S 06120 Germany Details
Novartis Investigative Site Hamburg 20249 Germany Details
Novartis Investigative Site Ulm 89081 Germany Details
Novartis Investigative Site Thessaloniki 540 07 Greece Details
Novartis Investigative Site Thessaloniki 57001 Greece Details
Novartis Investigative Site Budapest H 1122 Hungary Details
Novartis Investigative Site Budapest H-1097 Hungary Details
Novartis Investigative Site Debrecen 4032 Hungary Details
Novartis Investigative Site Jerusalem 9112001 Israel Details
Novartis Investigative Site Ramat Gan 52621 Israel Details
Novartis Investigative Site Tel Aviv 6423906 Israel Details
Novartis Investigative Site Firenze FI 50134 Italy Details
Novartis Investigative Site Milano MI 20133 Italy Details
Novartis Investigative Site Milano MI 20162 Italy Details
Novartis Investigative Site Verona VR 37126 Italy Details
Novartis Investigative Site Nagoya Aichi 464 8681 Japan Details
Novartis Investigative Site Kashiwa Chiba 277 8577 Japan Details
Novartis Investigative Site Yokohama-city Kanagawa 241-8515 Japan Details
Novartis Investigative Site Osaka-city Osaka 541-8567 Japan Details
Novartis Investigative Site Chuo ku Tokyo 104 0045 Japan Details
Novartis Investigative Site Koto ku Tokyo 135 8550 Japan Details
Novartis Investigative Site Seoul Seocho Gu 06591 Korea, Republic of Details
Novartis Investigative Site Seoul 03080 Korea, Republic of Details
Novartis Investigative Site Seoul 05505 Korea, Republic of Details
Novartis Investigative Site Utrecht 3543 AZ Netherlands Details
Novartis Investigative Site Nordbyhagen Oslo 1478 Norway Details
Novartis Investigative Site Oslo NO-0407 Norway Details
Novartis Investigative Site Omsk 644013 Russian Federation Details
Novartis Investigative Site Pushkin Saint Petersburg 196603 Russian Federation Details
Novartis Investigative Site Singapore 168583 Singapore Details
Novartis Investigative Site Bratislava Slovak Republic 83310 Slovakia Details
Novartis Investigative Site Banska Bystrica 975 17 Slovakia Details
Novartis Investigative Site Kosice 041 91 Slovakia Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Hospitalet de LLobregat Catalunya 08907 Spain Details
Novartis Investigative Site Santiago De Compostela Galicia 15706 Spain Details
Novartis Investigative Site Madrid 28009 Spain Details
Novartis Investigative Site Madrid 28034 Spain Details
Novartis Investigative Site Madrid 28040 Spain Details
Novartis Investigative Site Malmo SE-205 02 Sweden Details
Novartis Investigative Site Umea 901 85 Sweden Details
Novartis Investigative Site Bellinzona 6500 Switzerland Details
Novartis Investigative Site Geneve 14 CH 1211 Switzerland Details
Novartis Investigative Site St Gallen 9007 Switzerland Details
Novartis Investigative Site Taipei 10002 Taiwan Details
Novartis Investigative Site Taipei 11217 Taiwan Details
Novartis Investigative Site Taoyuan 33305 Taiwan Details
Novartis Investigative Site Adana 01250 Turkey Details
Novartis Investigative Site Ankara 06230 Turkey Details
Novartis Investigative Site Istanbul 34722 Turkey Details
Novartis Investigative Site Izmir 35100 Turkey Details
Novartis Investigative Site Sutton Surrey SM2 5PT United Kingdom Details
Novartis Investigative Site Cambridge CB2 0QQ United Kingdom Details
Novartis Investigative Site Liverpool CH63 4JY United Kingdom Details
Novartis Investigative Site London EC1A 7BE United Kingdom Details
Novartis Investigative Site Oxford OX3 7LE United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field